Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT04209855 2025-08-27

MIRASOL

Phase 3 Completed

453 enrolled 18 charts 1 FDA

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06994195 2025-08-17

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

384 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04498117 2025-07-09

FLORA-5

Phase 3 Active not recruiting

615 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Clinical Trials

KEYNOTE-B96

OVATION 2

OVATION-3

Study of INCB123667 in Subjects With Advanced Solid Tumors

TREVI-OC-01

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

A Study of NX-1607 in Adults With Advanced Malignancies

MIRASOL

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

FLORA-5